CLOFAZIMINE

作品数：4被引量：1H指数：1
导出分析报告
相关机构：德克萨斯大学更多>>
相关期刊：《Research》《Acta Biochimica et Biophysica Sinica》《Asian Pacific Journal of Tropical Medicine》《Acta Pharmaceutica Sinica B》更多>>
相关基金：国家自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-4
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Eclipsing Toxicity,Enhancing Efficacy:Clofazimine's Vanguard in the Realm of Anti-PD-1 and CTLA-4 Immunotherapy
《Research》2025年第1期631-633,共3页Ruirong Tan Junning Zhao Quazi T.H.Shubhra 
Cancer’s unrelenting grip on global health drives the relentless pursuit of innovative therapies to improve patient outcomes[1].Among these advancements,immunotherapy—specifically immune checkpoint blockade(ICB)—ha...
关键词：EFFICACY immune checkpoint blockade icb immune system CLOFAZIMINE 
Treatment outcomes and adverse drug reactions among patients with drug-resistant tuberculosis receiving all-oral,long-term regimens:First record viewing report from Pakistan被引量：1
《Asian Pacific Journal of Tropical Medicine》2023年第2期58-64,I0003,共8页Hira Aslam Asad Omar Razia Fatima Usman Rasool Aashifa Yaqoob Waseem Ullah Aamir Khan Yusra Habib Khan Tauqeer Hussain Mallhi 
Objective:To assess the effectiveness and adverse drug reactions of all-oral regimens for patients with multidrug-resistant tuberculosis.Methods:This retrospective study was conducted at 10 Programmatic Management of ...
关键词：All-oral long-term regimens Long-term regimens Bedaquiline LINEZOLID CLOFAZIMINE Drug resistant tuberculosis Treatment outcomes aDSM 
Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance for Mycobacterium ulcerans
《Acta Pharmaceutica Sinica B》2021年第3期738-749,共12页Yamin Gao HMAdnan Hameed Yang Liu Lingmin Guo Cuiting Fang Xirong Tian Zhiyong Liu Shuai Wang Zhili Lu Md Mahmudul Islam Tianyu Zhang 
supported by the National Mega-Project of China for Innovative Drugs(2019ZX09721001-003-003);the Chinese Academy of Sciences grant(154144KYSB20190005,China);the Key-Area Research and Development Program of Guangdong Province(2019B110233003,China);the Special Funds for Economic Development of Marine Economy of Guangdong Province(GDME-2018C003,China);partially by the Grants(SKLRDOP-201919 and SKLRD-Z-202016)from the State Key Laboratory of Respiratory Disease,Guangzhou Institute of Respiratory Diseases,First Affiliated Hospital of Guangzhou Medical University,Guangzhou,China。
Buruli ulcer(BU),caused by Mycobacterium ulcerans,is currently treated with rifampin estreptomycin or rifampineclarithromycin daily for 8 weeks recommended by World Health Organization(WHO).These options are lengthy w...
关键词：Mycobacterium ulcerans Buruli ulcer Electron transport chain QcrB Chemotherapy TB47 Drug resistance CLOFAZIMINE 
Anti-leprosy drug Clofazimine binds to human Rafl kinase inhibitory protein and enhances ERK phosphorylation
《Acta Biochimica et Biophysica Sinica》2018年第10期1062-1067,共6页Chenyun Guo Ting Chang Tao Sun Zhihua Wu Yazhuang Dai Hongwei Yao Donghai Lin 
This work was supported by the grants from the Natural Science Foundation of China （Nos. 131470034 and 31670741） and the Fundamental Research Funds for the Central Universities （No. 20720160033）.
Human Rafl kinase inhibitory protein （hRKIP） is an important modulator of the Ras/Rafl/MEK/ERK signaling pathway. Here, we demonstrated that anti-leprosy drug Clofazimine can bind to hRKIP with a significantly stron...
关键词：CLOFAZIMINE hRKIP ERK phosphorylation BLI NMR 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部